TARO-CEFPROZIL 250 MG / 5 ML
CEFPROZIL (CEFPROZIL MONOHYDRATE) : 250 MG / 5 ML · DIN 02293579 · SUN PHARMA CANADA INC
Health Canada status: MARKETED
What is TARO-CEFPROZIL?
TARO-CEFPROZIL 250 MG / 5 ML contains CEFPROZIL (CEFPROZIL MONOHYDRATE) : 250 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02293579, held by SUN PHARMA CANADA INC, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Oct-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-CEFPROZIL used for?
Pharyngitis/tonsillitis, otitis media, acute sinusitis, uncomplicated skin and skin-structure infections, and uncomplicated urinary tract infections caused by susceptible organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02293579 |
|---|---|
| Brand name | TARO-CEFPROZIL |
| Generic / active ingredient | CEFPROZIL (CEFPROZIL MONOHYDRATE) : 250 MG / 5 ML |
| Manufacturer | SUN PHARMA CANADA INC |
| Strength | 250 MG / 5 ML |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01DC10 CEFPROZIL |
| AHFS class | 08:12.06.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Oct-2025 |
| Original market date | 2007-04-17 00:00:00 |
How is it administered?
Adults: 250-500mg q12h or q24h. Children (6mo-12yr): 7.5-15mg/kg q12h or 20mg/kg q24h. Administered orally with or without food. Max 1g/day for pediatrics. Duration usually 7-15 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Dry powder: 15-30°C, protect from light/humidity. Reconstituted suspension: Refrigerate (2-8°C) for up to 14 days.
How is it supplied?
Bottles of 50 mL, 75 mL and 100 mL.
Contraindications
Known allergy to the cephalosporin class of antibiotics or to any component of the Cefprozil preparations.
Warnings and precautions
Cross-sensitivity may occur in penicillin-sensitive patients (up to 10%). Risk of pseudomembranous colitis and severe cutaneous adverse reactions (SCAR). Risk of overgrowth of nonsusceptible organisms.
What can be used instead?
Other Canadian products sharing ATC code J01DC10 CEFPROZIL. 7 of 34 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-CEFPROZIL | 125 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | DIN 02347261 |
| AURO-CEFPROZIL | 250 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | DIN 02347288 |
| AURO-CEFPROZIL | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02347253 |
| SPC-CEFPROZIL | 250 MG | TABLET | SUN PHARMA CANADA INC | MARKETED | DIN 02293528 |
| SPC-CEFPROZIL | 500 MG | TABLET | SUN PHARMA CANADA INC | MARKETED | DIN 02293536 |
| TARO-CEFPROZIL | 125 MG / 5 ML | POWDER FOR SUSPENSION | SUN PHARMA CANADA INC | MARKETED | DIN 02329204 |
| APO-CEFPROZIL | 125 MG / 5 ML | POWDER FOR SUSPENSION | APOTEX INC | DORMANT | DIN 02293943 |
| APO-CEFPROZIL | 250 MG | TABLET | APOTEX INC | DORMANT | DIN 02292998 |
| APO-CEFPROZIL | 250 MG / 5 ML | POWDER FOR SUSPENSION | APOTEX INC | DORMANT | DIN 02293951 |
| APO-CEFPROZIL | 500 MG | TABLET | APOTEX INC | DORMANT | DIN 02293005 |
Who else supplies CEFPROZIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFPROZIL appears in 45 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.